Recommendations of Multiple Sclerosis and Neuroimmunology Section of Polish Neurological Society and Immuno-oncology Section of Polish Society of Oncology on oncological risk in patients with multiple sclerosis undergoing immunomodulatory therapy
Neurologia i Neurochirurgia Polska · 2025
DOI: 10.5603/pjnns.101995 ↗Kurz gefasst
Leitlinie in der Zeitschrift Neurologia i Neurochirurgia Polska, 2025. Verfasst von Iwona Rościszewska-Żukowska und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszow, Poland. iwona.rosciszewska@op.pl. Hauptthemen laut MEDLINE: Immunologic Factors, Immunomodulating Agents, Immunosuppressive Agents, Multiple Sclerosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref).
Abstract (Originalsprache)
Multiple sclerosis (MS) is an autoimmune demyelinating disease of the central nervous system (CNS) that is usually diagnosed between the ages of 20 and 40. Changes in the immune system also observed in cancer may suggest a higher prevalence of cancer in the MS patient population. In recent years, many highly effective immunosuppressive drugs have been introduced into disease-modifying therapy (DMT) which may be associated with a higher risk of cancer development in patients with MS. This paper presents current data on the oncological risk of individual drugs. In addition, it provides recommendations on the management for qualifying for DMT and monitoring the safety of the therapy from anoncological perspective.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszow, Poland. iwona.rosciszewska@op.pl.
- Department of Neurology, Medical University of Bialystok, Bialystok, Poland.
- Department of Neurology, Division of Neurochemistry and Neuropathology, Poznan University of Medical Sciences, Poznan, Poland.
- Department of Neurology, Institute of Medical Sciences, Medical College of Rzeszow University, Poland.
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland.
- Department of Neurology, Medical University of Lodz, Lodz, Poland.
ORCID-Profile: Iwona Rościszewska-Żukowska, Alina Kułakowska, Alicja Kalinowska, Halina Bartosik-Psujek, Dagmara Mirowska-Guzel, Mariusz Stasiołek, Waldemar Brola
Zitieren
APA
Rościszewska-Żukowska, I., Kułakowska, A., Kalinowska, A., Bartosik-Psujek, H., Mirowska-Guzel, D., Stasiołek, M., Zakrzewska-Pniewska, B., Brola, W., Wawrzyniak, S., Gołębiowski, M., Mackiewicz, J., Kamińska-Winciorek, G., Czarnecka, A. M., Maciejczyk, A., Giebel, S., Rutkowski, P., Cybulska-Stopa, B., & Adamczyk-Sowa, M. (2025). Recommendations of Multiple Sclerosis and Neuroimmunology Section of Polish Neurological Society and Immuno-oncology Section of Polish Society of Oncology on oncological risk in patients with multiple sclerosis undergoing immunomodulatory therapy. Neurologia i Neurochirurgia Polska. https://doi.org/10.5603/pjnns.101995
Vancouver
Rościszewska-Żukowska I, Kułakowska A, Kalinowska A, Bartosik-Psujek H, Mirowska-Guzel D, Stasiołek M, et al. Recommendations of Multiple Sclerosis and Neuroimmunology Section of Polish Neurological Society and Immuno-oncology Section of Polish Society of Oncology on oncological risk in patients with multiple sclerosis undergoing immunomodulatory therapy. Neurologia i Neurochirurgia Polska. 2025. doi:10.5603/pjnns.101995
BibTeX
@article{Rociszewskaukowska2025,
author = {Rościszewska-Żukowska, Iwona and Kułakowska, Alina and Kalinowska, Alicja and Bartosik-Psujek, Halina and Mirowska-Guzel, Dagmara and Stasiołek, Mariusz and Zakrzewska-Pniewska, Beata and Brola, Waldemar and Wawrzyniak, Sławomir and Gołębiowski, Marek and Mackiewicz, Jacek and Kamińska-Winciorek, Grażyna and Czarnecka, Anna M and Maciejczyk, Adam and Giebel, Sebastian and Rutkowski, Piotr and Cybulska-Stopa, Bożena and Adamczyk-Sowa, Monika},
title = {Recommendations of Multiple Sclerosis and Neuroimmunology Section of Polish Neurological Society and Immuno-oncology Section of Polish Society of Oncology on oncological risk in patients with multiple sclerosis undergoing immunomodulatory therapy},
journal = {Neurologia i Neurochirurgia Polska},
year = {2025},
doi = {10.5603/pjnns.101995}
}
EUVIMED